Co-incidence of Human Papillomaviruses and Epstein-Barr Virus Is Associated With High to Intermediate Tumor Grade in Human Head and Neck Cancer in Syria.
Epstein–Barr virus
Syrian population
head and neck cancers
human papillomaviruses
tumor grade
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
01
2020
accepted:
22
05
2020
entrez:
25
9
2020
pubmed:
26
9
2020
medline:
26
9
2020
Statut:
epublish
Résumé
High-risk human papillomaviruses (high-risk HPVs) have been recently reported to be co-present with Epstein-Barr virus (EBV) in different types of human cancers including head and neck (HN), where they can cooperate in the initiation and/or progression of this cancer. Accordingly, we herein explored the prevalence of high-risk HPVs and EBV in 80 HN cancer tissues from the Syrian population using polymerase chain reaction, immunohistochemistry, and tissue microarray methodologies. We report that high-risk HPVs and EBV are present in 35/80 (43.7%) and 41/80 (51.2%) of our samples, respectively, and the most frequent HPV types are 33, 16, 18, 45, 52, 58, 35, 51, and 31, in this order. More significantly, our data reveal that 25/80 (31.2%) of cancer cases are positive for high-risk HPVs as well as EBV, and their co-presence is associated with high/intermediate-grade squamous cell carcinomas. These data confirm the co-presence of high-risk HPVs and EBV in HN cancers in the Syrian population of the Middle East and demonstrate that their co-incidence is linked to a more aggressive cancer phenotype. Thus, future studies are required to confirm these data and elucidate the exact role of high-risk and EBV cooperation in human HN carcinogenesis.
Identifiants
pubmed: 32974123
doi: 10.3389/fonc.2020.01016
pmc: PMC7468388
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1016Informations de copyright
Copyright © 2020 Gupta, Ghabreau, Al-Thawadi, Yasmeen, Vranic, Al Moustafa and Malki.
Références
Mod Pathol. 2004 Nov;17(11):1314-22
pubmed: 15257311
Oncol Rep. 2014 Dec;32(6):2673-9
pubmed: 25241968
Biochem Biophys Res Commun. 2013 Jun 7;435(3):339-44
pubmed: 23628416
Rev Bras Epidemiol. 2016 Mar;19(1):160-6
pubmed: 27167657
Front Oncol. 2018 Jul 02;8:250
pubmed: 30035100
Nat Rev Cancer. 2004 Oct;4(10):757-68
pubmed: 15510157
Virol J. 2017 Apr 21;14(1):84
pubmed: 28431558
F1000Res. 2017 Jun 12;6:866
pubmed: 28663791
Int J Cancer. 2017 Jul 1;141(1):143-151
pubmed: 28369859
Hum Vaccin Immunother. 2016 Jul 2;12(7):1936-9
pubmed: 27082145
Cancer Res. 2007 Mar 1;67(5):1970-8
pubmed: 17332324
Pathol Res Pract. 2016 Nov;212(11):1021-1026
pubmed: 27640103
Cancer. 2005 Jun 25;105(3):171-7
pubmed: 15822131
Tumour Biol. 2015 Apr;36(4):3051-60
pubmed: 25501510
PLoS One. 2012;7(11):e48788
pubmed: 23183846
Exp Mol Pathol. 2006 Dec;81(3):231-4
pubmed: 16787643
Oncol Lett. 2012 Mar;3(3):667-671
pubmed: 22740973
Exp Dermatol. 2009 Dec;18(12):1067-9
pubmed: 19397698
J Oral Pathol Med. 2015 Jan;44(1):28-36
pubmed: 25040496
PLoS One. 2014 Nov 18;9(11):e113702
pubmed: 25405488
Histopathology. 2015 May;66(6):771-80
pubmed: 25039283
Int J Mol Sci. 2017 Dec 19;18(12):
pubmed: 29257122
JNCI Cancer Spectr. 2019 Jan 07;2(4):pky045
pubmed: 31360870
Hum Vaccin Immunother. 2020 Mar 18;:1-5
pubmed: 32186955
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Oncogenesis. 2017 Dec 22;6(12):402
pubmed: 29284791
PLoS One. 2016 Aug 05;11(8):e0160698
pubmed: 27494179
Radiother Oncol. 2015 Sep;116(3):342-5
pubmed: 26364887
Infect Agent Cancer. 2018 Nov 9;13:32
pubmed: 30455727
Front Oncol. 2018 May 01;8:111
pubmed: 29765906
Laryngoscope. 2004 Jun;114(6):1027-31
pubmed: 15179207
Infect Agent Cancer. 2011 Feb 25;6(1):3
pubmed: 21352537
Trends Microbiol. 2016 Aug;24(8):649-664
pubmed: 27068530
J Exp Clin Cancer Res. 2006 Dec;25(4):515-21
pubmed: 17310842
Br J Cancer. 2011 Mar 29;104(7):1160-7
pubmed: 21386845
Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36
pubmed: 12482570
Head Neck. 2019 Feb;41(2):349-357
pubmed: 30549170
Sci Rep. 2016 Feb 12;6:21039
pubmed: 26868772
Oncotarget. 2015 Sep 29;6(29):26995-7007
pubmed: 26336991
J Cancer Educ. 2015 Sep;30(3):546-51
pubmed: 25398667
Cancer. 2018 Feb 1;124(3):530-536
pubmed: 29072774
Lancet Oncol. 2012 Jun;13(6):607-15
pubmed: 22575588
Rev Med Virol. 2014 May;24(3):142-53
pubmed: 24339346
J Clin Oncol. 2013 Dec 20;31(36):4550-9
pubmed: 24248688
Expert Rev Vaccines. 2017 Nov;16(11):1119-1139
pubmed: 28956458
Hum Vaccin Immunother. 2014;10(7):1812-21
pubmed: 25424787
Anticancer Res. 2012 Feb;32(2):571-80
pubmed: 22287747
Int J Gynecol Cancer. 2004 Sep-Oct;14(5):896-902
pubmed: 15361201
Int J Cancer. 2011 Jul 15;129(2):433-9
pubmed: 20839262
Clin Microbiol Infect. 2010 Mar;16(3):262-6
pubmed: 19438642
Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):126-137
pubmed: 30605716
Expert Rev Vaccines. 2018 Mar;17(3):239-248
pubmed: 29313728
FASEB J. 2016 Sep;30(9):3001-10
pubmed: 27279361
PLoS Pathog. 2010 Jun 03;6(6):e1000940
pubmed: 20532215
Br J Cancer. 2008 Aug 5;99(3):404-7
pubmed: 18648363
Int J Exp Pathol. 2001 Jun;82(3):149-70
pubmed: 11488990
Laryngoscope. 2002 Mar;112(3):482-7
pubmed: 12148858